{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:09Z","timestamp":1791216009932,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Canadian Fabry Association"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.ymgme.2014.01.014","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T21:32:58Z","timestamp":1391376778000},"page":"499-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Outcomes of patients treated through the Canadian Fabry disease initiative"],"prefix":"10.1016","volume":"111","author":[{"given":"S.M.","family":"Sirrs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2014.01.014_bb0175","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0010","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized, controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alfa-galactosidase: a replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0025","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"7","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0240","author":"Canadian Expert Drug Advisory Committee"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0255","author":"Canadian Expert Drug Advisory Committee"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0050","first-page":"1","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"2","author":"El Dib","year":"2013","journal-title":"Cochrane Libr."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0190","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0195","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","article-title":"Baseline characteristics of subjects enrolled in the Canadian Fabry disease initiative","volume":"99","author":"Sirrs","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human \u03b1-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0200","first-page":"517A","article-title":"Cross-sectional analysis of renal disease in the Nova Scotia Fabry disease kindred","volume":"13","author":"West","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1651-2227.2002.tb03152.x","article-title":"Renal transplantation in the Nova Scotia Fabry disease kindred","volume":"19","author":"West","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0080","first-page":"418","article-title":"A Nova Scotia kindred with Fabry disease","volume":"71","author":"West","year":"2002","journal-title":"Amer. J. Hum. Gen."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0245","author":"West"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0260","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural history of Fabry disease: changing patterns and causes of death in FOS \u2014 Fabry Outcomes Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med Genet."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2014the Fabry outcome survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0265","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in subjects with Fabry's disease: an analysis of registry data","volume":"274","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","article-title":"Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult subjects, enzymereplacement, and support therapy","volume":"31","author":"Salviati","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in subjects with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0250","author":"Lysosomal Storage Diseases Expert Advisory Group"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0270","author":"Anonymous"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0130","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart, and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0145","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1590\/S1415-47572012000600009","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis","volume":"35","author":"Alegra","year":"2012","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0150","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10545-011-9428-z","article-title":"Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry subjects","volume":"35","author":"Nicholls","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0155","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ymgme.2014.01.014_bb0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2007.10.009","article-title":"Experimental and clinical basis for the use of statins in subjects with ischemic and nonischemic cardiomyopathy","volume":"51","author":"Ramasubbu","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0165","doi-asserted-by":"crossref","first-page":"10A","DOI":"10.1016\/j.amjcard.2009.10.006","article-title":"Progression of cardiovascular damage: the role of renin-angiotensin system blockade","volume":"105","author":"Probstfield","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in subjects with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2014.01.014_bb0275","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719214000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:03:56Z","timestamp":1716487436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719214000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1096719214000407"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.01.014","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of patients treated through the Canadian Fabry disease initiative","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2014.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}